WHY NOW
Verified recent context
0 itemsNo verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.
WHY THIS GROUP EXISTS
Shared filing context
10/10 members coveredModerate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across A, CRL, MTD, RGEN, SHC, TMO, WAT.
restructuring affecting expense
“A summary of the charges in the condensed consolidated statement of operations resulting from restructuring activity is shown below: Three Months Ended Six Months Ended April 30, April 30, 2026 2025 2026 2025 (in millions) Cost of products and services $ 3 $ 15 $ 8 $ 15 Research and development — 3 — 3 Selling, general and administrative (1) 5 38 20 39 Total restructuring expense $ 8 $ 56 $ 28 $ 57 ___________________________________________________________________________________________________ (1) For the six months ended April 30, 2025, selling, general and administrative expense includes restructuring expense of $1 million related to the fiscal year 2024 restructuring plan that was completed in fiscal year 2025.”
A 10-Q · 2026-06-01
demand / volume affecting revenue
“The revenue decline in Asia Pacific was driven by lower demand in China within our gas chromatography, spectroscopy and vacuum businesses partially offset by strength in the gas chromatography mass spectrometry and remarketed instruments businesses in China when compared to the same period last year.”
A 10-K · 2025-12-22
credit / rates affecting interest expense
“We are also exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments.”
A 10-Q · 2026-06-01
CONFIRMATION NETWORK
Outsiders and cross-asset links
6 outsiders confirmingA → UVXYPositive historical lead/lag · strength 0.24
A → HYGInverse historical lead/lag · strength -0.19
Filing-linked outsiders test whether the move is spreading beyond the established cohort.
DHR · partner
Filing receipt
“Michael Feld 45 Executive Vice President and President, Life Sciences since August 2024; President of Hach (Veralto Corporation) from September 2023 to August 2024; Seni…”
DHR · partner
Filing receipt
“In connection with the Separation, the Company entered into certain agreements with Danaher, including a tax matters agreement.”